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Case Report
AbstractMultiple endocrine neoplasia are syndromes involving two or more endocrine tissues, often correlated to RETproto-oncogene mutations. We herein present the first reported case of a 57-years-old woman with three synchronousprimary cancers of breast (papillary), thyroid (medullary) and pancreas (neuroendocrine), the latter with livermetastasis. The patient first underwent surgery for papillary breast cancer with axillary lymph nodes metastases. Astaging whole body computerized tomography (CT) showed a right lateral cervical lymph node, pancreaticinhomogeneity, peri-pancreatic nodes and a single liver metastasis. The poor response to an antracycline andtaxane-based chemotherapy, the good performance status of patient, and associated symptoms, suggested a differentorigin for pancreatic and hepatic lesions. A careful re-evaluation of clinical history, an octreotide-labeled scan and animmunohistochemical analysis, on both hepatic and pancreatic tissues and on laterocervical lymph node, determinedthe diagnosis of synchronous papillary breast cancer, pancreatic neuroendocrine tumor (pNET) with liver metastasisand an occult medullary thyroid carcinoma in a patient who had proto-oncogene RET wild type.
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IntroductionMultiple endocrine neoplasia (MEN) are autosomaldominant syndromes characterized by tumors involvingtwo or more endocrine tissues. Two, among thesesyndromes, have been clinically and genetically wellcharacterized: the MEN type 1 (MEN1) and type 2(MEN2), which are caused by germline mutations in theMEN1 tumor suppressor gene and in the RET(Rearranged during Transfection) proto-oncogene,respectively.1 However, uncommon situations ofmultiple synchronous cancers, without evidentcorrelation with a particular genetic mutation, can alsooccur, such as atypical MENS. We herein present aclinical entity of three synchronous primary cancers ofthe breast (papillary), thyroid (medullary) and pancreas(neuroendocrine), the latter with liver metastasis.
Case presentationOn February 2001, a well-being 57-year-old womanunderwent left mastectomy and axillary lymph nodesdissection. Histology revealed a completely excised, 11
mm of diameter, grade 2, invasive breast papillarycarcinoma with metastatic involvement of 2, among the17 examined, axillary lymph nodes. The TNMclassification was pT1c pN1 (2/17) pMx; estrogenreceptor (ER) and progesterone receptor (PR) werenegative, Ki 67 index was 20%, Her2 was negative, aswell as synaptophysin.Staging radiological examinations were performed and acomputerized tomography (CT) scan showed metastaticinvolvement of a right lateral cervical lymph node,inhomogeneity of the pancreatic head with loco-regionallymph nodes involvement and the presence of a singlelarge (8 cm in diameter) hepatic metastasis on the lefthepatic lobe. The patient received a first linechemotherapy for metastatic breast cancer, with anantracycline and taxane-based regimen, and she reachedonly a stable disease.She was then suffering persistent heartburn and emesis,responsive only to anti H2 antagonists, flushing and
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neck swelling. Therefore, an esophagogastroduodenos-copy was carried out, which resulted negative.Serological evaluation of CEA (carcinoembryonicantigen), neuron specific enolase (NSE),5-hydroxyindoleacetic acid (5-HIAA) and thyroglobulinwas negative, but the patient presented high serumlevels of calcitonin (58 pg/ml, normal range < 15 pg/ml)and weakly positive chromogranin A values (126 ng/ml,normal range 0-90 ng/ml).Somatostatin receptor scintigraphy (Octreoscan), asensitive method for the detection of neuroendocrinetumors and metastases bearing the somatostatinreceptor subtypes 2 (SSTR2) or SSTR 5, demonstratedhigh density of somatostatin receptors in the rightthyroid-parathyroid area, in the right neck, induodeno-pancreatic region and in a focal hepatic site.We then performed a fine needle aspiration of theenlarged lateral cervical lymph node, and a liver andpancreatic biopsy. Lateral cervical lymph nodecytological examination revealed numerous singlyarranged cells of plasmacytoid appearance,immunoreactive for calcitonin: these findings wereconsistent with a metastatic thyroid medullarycarcinoma. Histopathological evaluation of thepancreatic and liver biopsies established a diagnosis ofprimary pancreatic well-differentiated neuroendocrinetumor, grade 2 according to WHO (2010), withmetastatic involvement of the liver. The tumor showed alow mitotic count (2/10 high- power field HPF).Immunohistochemical analysis of both tissues showed aKi67 index of 5%, diffuse synaptophysin and focalchromogranin A (Figure 1a) expression in the tumor cellcomponent (Figure 1b). Yet, RET resulted wild type. Thepatient underwent radical thyroidectomy and lateralcervical lymph node dissection and histology showed amedullary carcinoma, measuring 2.5 cm diameter, with> 25% calcitonin immunopositive cells in the thyroid.Additionally, 2 out of the 10 examined loco-regionalnodes were involved by metastatic disease (TNMclassification pT2 pN1 pMx).
Figure 1: a) Cromogranin A immunoperoxidase staining ofmetastatic liver. b) Higher magnification histology ofmetastatic tumor cells into the liver.Surgery of the pancreatic neuroendocrine tumor wascontraindicated, due to the liver metastasis extensionand location. Therefore, the patient received achemotherapy regimen based on streptozotocin and
5-fluorouracil for 6 cycles, achieving a clinical partialresponse.In relation to the histological and immunohistochemicalfeatures of the pancreatic tumor (mitotic count of 2/10HPF, Ki67 index of 5%, synaptophysin +, chromograninA+/-) and to the high density of somatostatin receptorson Octreoscan analysis, the patient was also started to atreatment with long-acting Octreotide (LAR) 30 mgintramuscularly every 28 days, without toxicities andmaintaining clinical partial response. Presently, she isstill alive, with a good performance status andpreserving a good quality of life. Continuing treatmentwith long-acting Octreotide did not result in systemictoxicities, and allowed for good control of metastaticneuroendocrine carcinoma, with biochemical andsymptomatic responses.
DiscussionWe present an intriguing clinical entity of a combinedsynchronous primary papillary breast carcinoma,thyroid medullary carcinoma and pancreaticwell-differentiated neuroendocrine tumor that has not,to our knowledge, previously been reported.Our patient was affected by an unusual variety of ductalcarcinoma, the papillary histotype. Its incidence rangesfrom 0, 5 to 2% of all newly diagnosed breast cancers. Itusually occurs in women aged between 50 and 70 years,and it is characterized by a good prognosis with a longterm survival.2 Antracyclines and taxanes are some ofthe most active agents against advanced breast cancer;the obtainment of a stable disease instead than anobjective response to this chemotherapy in the presentcase called into question the diagnosis, so we decided toundergo further examinations for a better evaluation ofthe patient’s disease.In breast cancer patients a high prevalence of thyroiddiseases, particularly Hashimoto's thyroiditis, has beendescribed, whose relationship and coincidence is still asubject of extensive debate and controversy.3To a morecareful evaluation of the literature we found two cases ofsynchronous breast and medullary thyroid cancer.4These patients presented high serum CEA levels, andwere affected by the usual ductal-type variety of breastcarcinoma, differently from the present case. Therefore,the finding of a synchronous thyroid medullarycarcinoma was rather unexpected.Medullary thyroid carcinoma is an APUDoma (AminePrecursor Uptake and Decarboxylation) arising from theparafollicular C cells. It is sporadic in 75% of cases, andfamilial in 25%, due to RET proto-oncogene germinalmutations. The familial form of medullary thyroidcarcinoma can also be a component of multipleendocrine neoplasia (MEN) IIA or IIB. Serum calcitoninvalue is an important diagnostic tool for thyroid cancer
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and high levels are usually found in the medullarythyroid cancer.5Neuroendocrine tumors (NETs) are rare neoplasms,with an incidence of about 1 case per 100,000 in thepopulation per year, with variations due to theirhistotype.6 Recently, an increase in the incidence ofthese tumors has been observed, from 1.09 to 5.25 casesper 100,000 in the USA population per year.7 In 70% ofthe cases, NETs are highly differentiated tumors, and arecharacterized by long patient’s survival. They can besporadic or familial diseases.6The peculiar association of such unusual tumors,suggested a careful genetic evaluation, despite hernegative family history, that revealed no first-degreerelatives with history of cancer. RET proto-oncogeneanalysis surprisingly indicated that the patientexpressed wild type RET, ruling out a MEN syndrome,not excluding a case of atypical MEN. However, asmedullary thyroid cancer has a common origin withneuroendocrine tumors, this patient could harborgenetic alterations other than RET germinal mutations.Recent literature reported, for example, the expressionof Kit protein and CD34 and the mutation of Kit receptortyrosine kinase gene in multiple endocrine neoplasia.6Gastro-entero-pancreatic neuroendocrine tumors can beassociated to other synchronous or metachronousprimary epithelial malignancies, accounting for about10% of cases, and, even less frequently (1.3% cases),they can be associated to non-epithelial neoplasms.7Nuclear imaging by Octreoscan plays a key role in thediagnosis of NETSs. Therapy with somatostatin analogs,such as long-acting repeatable octreotide (LAR), canimprove symptoms and stabilize tumor growth in manypatients. Results from the PROMID study showed thatLAR octreotide is an effective molecule for patients withnewly diagnosed, functionally active or inactive, well-differentiated metastatic midgut NETs.8 CLARINET studyconducted on 200 patients with metastaticenteropancreatic neuroendocrine tumors treated withlanreotide demonstrated a significantly prolongedprogression-free survival.9The use of LAR octreotide instead of standard octreotidedemonstrated an improvement in tumor mass decreaseand survival prolongation with long acting molecules.10This new formulation requires only one monthlyintramuscular injection, and shows better acceptabilityand patient compliance to therapy, so it seemspreferable in clinical practice. Indeed, minimal adverseeffects of somatostatin analogs permitted to our patienta prolonged treatment period without alteration of herquality of life.
ConclusionOur case report highlights an unusual association ofmultiple synchronous tumors, all characterized by lowincidence. This case suggests that sometimes atypicalforms of MEN with wild type RET can remainundiagnosed and that a neuroendocrine tumor shouldbe kept in mind when facing with a patient with anextensive disease, not responsive to key-drugs.
Conflict of interestThe authors declare that they have no conflicts ofinterest. The authors alone are responsible for thecontent and writing of the paper.
References1. Lodish MB, Stratakis CA. RET oncogene in MEN2,MEN2B, MTC and other forms of thyroid cancer.Expert Rev Anticancer Ther. 2008; 8:625-32.2. Pal SK, Lau SK, Kruper L, et al. Papillary carcinomaof the breast: an overview. Breast Cancer Res Treat.2010; 122:637-45.3. Tanaka H, Tsukuma H, Koyama H, et al. Secondprimary cancers following breast cancer in theJapanese female population. Jpn J Cancer Res. 2001;92:1-8.4. Andry G, Wildschutz T, Chantrain G, et al. ElevatedCEA in breast cancer patients with overlookedmedullary thyroid carcinoma. Eur J Surg Oncol.1993; 19:305-8.5. Costante G, Meringolo D, Durante C, et al. Predictivevalue of serum calcitonin levels for preoperativediagnosis of medullary thyroid carcinoma in acohort of 5817 consecutive patients with thyroidnodules. J Clin Endocrinol Metab. 2007; 92: 450-5.6. Cirillo F. Neuroendocrine tumors and theirassociation with rare tumors: observation of 4cases. Eur Rev Med Pharmacol Sci. 2010; 14:577-88.7. Yao JC, Hassan M, Phan A. One hundred years after“carcinoid”: epidemiology of and prognostic factorsfor neuroendocrine tumors in 35,825 cases in theUnited States. J Clin Oncol. 2008; 26: 3063-72.8. Rinke A, Müller HH, Schade-Brittinger C, et al.Placebo-controlled, double-blind, prospective,randomized study on the effect of octreotide LAR inthe control of tumor growth in patients withmetastatic neuroendocrine midgut tumors: a reportfrom the PROMID Study Group. J Clin Oncol. 2009;27:4656-63.9. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide inmetastatic enteropancreatic neuroendocrinetumors. N Engl J Med. 2014; 371: 224-33.10. Dogliotti L, Tampellini M, Stivanello M, et al. Theclinical management of neuroendocrine tumorswith long-acting repeatable (LAR) octreotide:comparison with standard subcutaneous octreotidetherapy. Ann Oncol. 2001; 12Suppl 2:S105-9.
